These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3008319)

  • 1. IgM immune complexes, lymphocytotoxins, and rheumatoid factors in renal transplant recipients with CMV disease.
    Baldwin WM; Claas FH; van Gemert GW; Westedt ML; van Es A; Daha MR; Paul LC; van Es LA
    Scand J Urol Nephrol Suppl; 1985; 92():9-13. PubMed ID: 3008319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections.
    Baldwin WM; van Es A; Valentijn RM; van Gemert GW; Daha MR; Vanes LA
    Clin Exp Immunol; 1982 Dec; 50(3):515-24. PubMed ID: 6299633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal graft dysfunction during infection with cytomegalovirus: association with IgM lymphocytotoxins and HLA-DR3 and DR7.
    Baldwin WM; Claas FH; van Es A; Westedt WL; van Gemert G; Daha MR; van Es LA
    Br Med J (Clin Res Ed); 1983 Nov; 287(6402):1332-4. PubMed ID: 6315125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new C1q solid-phase assay for the detection of IgM immune complexes: application to the follow-up of kidney graft recipients with recurrent cytomegalovirus infection.
    Basson J; Tardy JC; Aymard M
    J Clin Lab Immunol; 1990 Jan; 31(1):43-9. PubMed ID: 1966984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of rheumatoid factors in renal transplant recipients with cytomegalovirus infection and not with rejection.
    Baldwin WM; Westedt ML; van Gemert GW; Henny FC; Paul LC; Daha MR; van Es LA
    Transplantation; 1987 May; 43(5):658-62. PubMed ID: 3033854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgM anti-IgM cold lymphocytotoxins to B cells.
    Cicciarelli JC; Chia D; Terasaki PI; Barnett EV; Shirahama S
    Transplant Proc; 1979 Dec; 11(4):1950-3. PubMed ID: 316939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients.
    Kraat YJ; Stals FS; Christiaans MH; Lazzarotto T; Landini MP; Bruggeman CA
    J Med Virol; 1996 Mar; 48(3):289-94. PubMed ID: 8801292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Specific IgM of cytomegaloviruses and primary infection in kidney transplant patients].
    Devillechabrolle A; Nguyen TT; Luciani J; Frantz P; Huraux JM
    Pathol Biol (Paris); 1987 Oct; 35(8):1123-6. PubMed ID: 2825100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients.
    Bavinck JN; Gissmann L; Claas FH; Van der Woude FJ; Persijn GG; Ter Schegget J; Vermeer BJ; Jochmus I; Müller M; Steger G
    J Immunol; 1993 Aug; 151(3):1579-86. PubMed ID: 8393047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The internal image of IgG in cross-reactive anti-idiotypic antibodies against human rheumatoid factors.
    Fong S; Gilbertson TA; Carson DA
    J Immunol; 1983 Aug; 131(2):719-24. PubMed ID: 6863929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
    Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel AA; Yefenof E
    Bone Marrow Transplant; 1996 Feb; 17(2):237-41. PubMed ID: 8640173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
    Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
    J Mol Recognit; 1999; 12(5):249-57. PubMed ID: 10777254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
    Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
    J Mol Recognit; 1999; 12(4):249-57. PubMed ID: 10440996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
    Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
    Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Performance of the IgG avidity test in patients with cytomegalovirus disease].
    Lafarga B; Noguera FJ; Bolanos M; Pérez MC; Rodríguez H
    Enferm Infecc Microbiol Clin; 1997 Apr; 15(4):190-5. PubMed ID: 9312277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perivascular deposits of IgM in the skin of transplant recipients during active cytomegalovirus infections. Correlation with IgM rheumatoid factors and IgM immune complexes.
    Baldwin WM; Westedt ML; Vermeer BJ; Weening JJ; van Gemert GW; Boom BW; Paul LC; Daha MR; van Es LA
    Transplantation; 1987 Oct; 44(4):519-23. PubMed ID: 2823423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human monoclonal anti-cytomegalovirus antibodies].
    Seigneurin JM; Desgranges C
    Ann Med Interne (Paris); 1987; 138(5):343-6. PubMed ID: 2823659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.
    Doekes G; Schouten J; Cats A; Daha MR
    Immunology; 1985 Jul; 55(3):555-64. PubMed ID: 4018839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.